Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Saxenda is approved for: Adults Adults with obesity (BMI of 30 kg/m or greater) Adults who are overweight (BMI of 27 kg/m or greater) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol Children aged 12 and older Adolescents with obesity who weigh more than 60 kg (132 pounds) Limitations of use Saxenda should not be used together with other medicines that contain liraglutide, such as Victoza, or with any other GLP-1 receptor agonist, such as Ozempic, Wegovy, or Trulicity The safety and effectiveness of Saxenda in children aged 12 to 17 years who have type 2 diabetes have not been established
As with other incretin-based therapies, the most commonly reported side effects include nausea, vomiting, diarrhea and constipation, particularly during dose escalation
Biochem Pharmacol (2020) 180:114147
The clinic follows structured safety and prescribing protocols, partnering with board-certified physicians and FDA-regulated 503A compounding pharmacies
On 19 March 2026, the FDA approved a higher-dose formulation of semaglutide, Wegovy HD, at 7.2 mg for once-weekly subcutaneous administration
Safety Position : Neither Eli Lilly nor independent investigators have endorsed higher doses
US$ 27.25
US$ 29.09
US$ 28.12
US$ 24.13
US$ 22.43
US$ 21.72
US$ 24.27
US$ 22.52
US$ 24.21
US$ 29.20
US$ 20.76
